Generate Biomedicines Inc. to Present at Multiple Investor Conferences in September

SOMERVILLE, Mass., Sept. 08, 2026 /CourierPR/ -- Generate Biomedicines Inc. is scheduled to participate in several investor conferences in September, aiming to provide updates on its progress and showcase its innovative generative biology platform.

The company’s management team will present at the Cantor Global Healthcare Conference on Wednesday, September 9, at 3:55 p.m. Eastern Time. On Monday, September 14, Generate Biomedicines will also present at the Morgan Stanley 24th Annual Global Healthcare Conference at 7:00 a.m. Eastern Time. The following day, the team will address attendees at the Goldman Sachs Life Sciences Symposium on Tuesday, September 15, at 9:05 a.m. Eastern Time. On Wednesday, September 16, Generate Biomedicines will present at the H.C. Wainwright 28th Annual Global Investment Conference at 10:30 a.m. Eastern Time. Lastly, the company will participate in the Bernstein Insights Healthcare Leaders and Disruptors conference on Wednesday, September 23, at 8:00 a.m. Eastern Time.

Attendees of these conferences will have the opportunity to view live webcasts of the presentations on the "Events & Presentations" page within the Investors section of Generate Biomedicines’ website, accessible at investors.generatebiomedicines.com. A replay of the webcasts will be available for 90 days following the event.

Generate Biomedicines Inc. is a clinical-stage generative biology company founded in 2018. The company uses machine learning, biological engineering, and medicine to develop innovative therapeutics through its generative biology platform. This platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address undruggable and hard-to-drug targets, as well as known targets in new and more effective ways.

Generate Biomedicines has a broad pipeline across multiple therapeutic areas and protein-based modalities, addressing health challenges that are out of reach with traditional approaches. The company’s platform is expected to drive the advancement of its product candidates and contribute to the development of more effective treatments for patients.

The webcasts of the presentations will provide investors and attendees with insights into the company’s strategic direction and the progress of its research and development efforts. These events are seen as key milestones in the company’s efforts to raise awareness and attract investment in its innovative technologies.